On August 6, 2025, Nature published groundbreaking research from Harvard Medical School, led by Professor Bruce A. Yankner. The study identifies a Lithium Orotate Breakthrough, showing that a decline in brain lithium (Li) levels may be an early trigger of Alzheimer’s disease. In mild cognitive impairment, lithium levels were already significantly reduced and trapped in pathological plaques.
The research found that lithium orotate, a highly bioavailable form of lithium, was the most effective in animal models. It significantly improved memory, reduced disease pathology, reversed plaques, restored synapses, and revived memory. Unlike decades of research focused solely on amyloid-beta plaques, tau tangles, and genetic risk factors, this discovery spotlights lithium as one of the earliest reversible molecular events in Alzheimer’s disease.
Key Findings
Lithium Deficiency as an Early Event
In the prefrontal cortex of patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD), lithium levels were significantly lower than in healthy controls. This loss occurs early in the disease and correlates with cognitive decline.
Lithium “Hijacked” by Amyloid-Beta
Abnormal amyloid-beta (Aβ) plaques capture lithium ions, reducing the amount of “free lithium” available in the brain. As the disease progresses, lithium deficiency worsens, creating a vicious cycle: lithium loss → increased Aβ deposition → further lithium depletion.
Aβ Deposition “Seizes” Lithium, Leading to Functional Loss
-
LA-ICP-MS analysis showed that lithium is significantly enriched within amyloid-beta (Aβ) plaques in the brains of AD patients, while markedly reduced in non-plaque regions.
-
Mouse model experiments confirmed that Aβ selectively binds lithium, causing a sharp drop in available lithium levels.
This process creates a vicious cycle:
Lithium deficiency → reduced inhibition of GSK3β → decreased β-catenin activity → neuronal dysfunction → increased Aβ production → more lithium sequestration.
Multi-System Pathology from Lithium Deficiency
Low lithium levels lead to synapse loss, myelin damage, microglial inflammation, and excessive tau protein phosphorylation. These changes align with the hallmark pathologies of AD.
Breakthrough with a Novel Lithium Supplement
Traditional lithium salts such as lithium carbonate are easily trapped by Aβ plaques, limiting their effectiveness. Lithium orotate, however, is less prone to Aβ binding and can effectively restore lithium levels. In mouse models, it reversed AD pathology, including reducing Aβ deposits, restoring synaptic function, and improving memory.
Based on these findings, the research team proposed a groundbreaking treatment concept: if lithium loss is an early driving force in Alzheimer’s disease, could lithium supplementation reverse the pathological process?
However, traditional lithium salts such as lithium carbonate have major drawbacks. They are also captured by amyloid plaques, preventing them from performing their physiological function. In addition, they require high daily doses (around 900 mg), which can cause kidney toxicity and thyroid toxicity.
The team identified a novel lithium compound: lithium orotate, with unique advantages. Lithium orotate is less prone to releasing free lithium ions, allowing it to evade capture by amyloid plaques and effectively cross the blood-brain barrier to enter neurons.
In multiple Alzheimer’s mouse models and in normal aging mice, lithium orotate showed remarkable therapeutic effects:
- 58% reduction in amyloid-beta deposition
- 63% improvement in abnormal tau phosphorylation
- Hippocampal synaptic density restored to 89% of normal levels
- Memory test performance improved 2.4-fold
Most strikingly, lithium orotate achieved these effects at only 1/1000th the dose of traditional lithium carbonate (about 0.9 mg). In a long-term 18-month treatment study, treated mice showed no signs of organ toxicity, overcoming the safety limitations of conventional lithium therapy.
Mechanistically, micro-dose lithium exerts protective effects through multiple pathways:
- Activating microglia to clear amyloid-beta
- Inhibiting GSK3β, a key kinase involved in tau hyperphosphorylation
- Maintaining neuronal synaptic plasticity
- Promoting myelin formation and repair
These synergistic actions collectively rebuild the brain’s anti-aging defense system.
Clinical Significance and Future Directions
This groundbreaking study fundamentally changes our understanding of the origins of Alzheimer’s disease. Lithium deficiency, as an early spark in disease onset, helps explain why amyloid-beta deposition is harmless in some individuals but devastating in others. The successful application of lithium orotate demonstrates that restoring trace element homeostasis in the brain to reverse neurological dysfunction is no longer just a dream.
“The broad impact of lithium on the various manifestations of Alzheimer’s disease is astonishing. I have never seen anything like this in my decades of research,” remarked Professor Yankner.
Where to buy bulk lithium orotate powder?
Lithium orotate currently has a niche market, and it may not be widely available from factories or suppliers in China. Since 2018, Cima Science Co., Ltd. has been producing high-quality lithium orotate powder in large quantities, ensuring consistent purity and reliable supply.
We maintain a 2-ton inventory ready for immediate shipment. If you require a price quote, COA (Certificate of Analysis), or a detailed specification sheet, please contact us via the email on the Contact Us page.
References
- Aron, L., Ngian, Z. K., Qiu, C., Choi, J., Liang, M., Drake, D. M., Hamplova, S. E., Lacey, E. K., Roche, P., Yuan, M., Hazaveh, S. S., Lee, E. A., Bennett, D. A., & Yankner, B. A. (2025). Lithium deficiency and the onset of Alzheimer’s disease. Nature. https://doi.org/10.1038/s41586-025-09335-x
